• Users Online: 284
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2015  |  Volume : 6  |  Issue : 1  |  Page : 19-26

Value of CD11a and CD18 in flow cytometric immunophenotypic diagnosis of acute promyelocytic leukemia

1 Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2 Department of Clinical Pathology, Tanta Cancer Center, Tanta, Egypt
3 Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Correspondence Address:
Ghada Gohary
King Faisal Specialist Hospital and Research Center, P. O. Box 3354, MBC: 64, Riyadh 11211
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1658-5127.155180

Rights and Permissions

As acute promyelocytic leukemia (APL) has the highest curability among different acute amyeloid leukemia (AML) subtypes and requires a unique form of treatment, it is important to quickly establish or exclude the diagnosis of this subtype of leukemia. Furthermore, accurate and rapid diagnosis of APL is critical due to its association with disseminated intravascular coagulation. Patients and methods: This study was conducted on 100 newly diagnosed AML M0-M3 patients and a comprehensive flow cytometric immunophenotypic (FCM IPT) analysis of their peripheral blood (PB) and/or bone marrow samples with the inclusion of CD18 and CD11a monoclonal antibodies was done. Results: Cases of AML-M3 did not express human leukocyte antigen (HLA)-DR, CD11a and CD18, a highly significant different finding compared to non M3 cases (P < 0.001). The positive predictive value (PPV), negative predictive value (NPV), specificity and sensitivity of HLA-DR, and CD34 negativity (alone and in combination) were lower than the PPV, NPV, specificity and sensitivity of the combined negativity HLA-DR, CD11a, and CD18 antigens. Conclusion: Testing for CD18 and CD11a in conjunction with routine diagnostic FCM IPT panel will append extra diagnostic power to FCM IPT in the differentiation of difficult cases of AML-M3 from AML-(M0-M2).

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded279    
    Comments [Add]    

Recommend this journal